This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Target-Date ETFs Could Make or Break XShares

XShares, the sponsor of the HealthShares family of ETFs, needs a big hit. Its new target-date exchange-traded funds, which offer one-stop shopping for investors with a specific time horizon, may just fit the bill.

The five TDAX Independence funds, which were developed in partnership with discount broker TD Ameritrade (AMTD - Get Report) and launched on the NYSE Monday, are the first ETFs aimed at this fast-growing segment of the retirement market. They are also the first ETFs to invest in both stocks and bonds.

XShares has struggled to find a market for HealthShares, launched in January, and has experienced some management turnover. Nat Wasserstein, president and head of development for XShares Advisors, left last month, just days before William Henson was hired as chief executive of the parent company, XShares Group. (The CEO post had previously never been filled.)

The 19 HealthShares are possibly the least successful ETFs launched this year and an embodiment of how betting on highly specialized products to stand out in a crowded industry can backfire.

Each Healthshare tracks a narrow sector of the biotech industry. As of Friday, the entire family had just $96.2 million in assets under management, with HealthShares Diagnostics (HHD) holding the most, at $32.7 million. That means the average assets under management for the remaining 18 funds comes to a paltry $3.5 million.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
TDX $28.99 2.26%
TDV $30.60 1.09%
TDH $28.98 1.62%
TDD $25.30 -0.68%
TDN $30.05 1.18%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs